Details:
The agreement will leverage Confo’s expertise in addressing two GPCR targets for which functional antibodies are needed. Confo’s ConfoBody-based technology platform aims to overcome the limitations of drug discovery on GPCRs.
Lead Product(s): Antibody Medicines
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 30, 2021